News
May 9, 2022

Polsinelli is pleased to announce Shareholder Mark T. Deming has been promoted to Chair of the firm’s Hatch-Waxman Litigation Practice Group. Deming, who has served as the practice group’s Vice Chair, will now lead the practice and team of attorneys who represent some of the world’s largest, best-known and most influential pharmaceutical companies.

In the time since being appointed to Vice Chair of Polsinelli’s Hatch-Waxman Practice in 2019, Deming has provided leadership and guidance to Polsinelli’s group of pharmaceutical counseling and litigation attorneys as they supported clients in an array of cases, from blockbuster products to smaller market and specialty pharmaceuticals in first-to-file and later-filer cases. The group has consistently received rankings from Patexia on its ANDA Litigation Intelligence Reports, including ranking No. 55 on its list of Best Performing Law Firms in 2021.

“We are grateful for Mark’s leadership and I am pleased to see him grow into this position as our Hatch-Waxman Litigation Practice Chair,” said Polsinelli Intellectual Property Department Chair Patrick C. Woolley. “Mark has greatly contributed to our practice’s national reputation since joining the firm more than ten years ago and I am honored he has agreed to take on this role to lead our team.”

Deming is an intellectual property attorney who advises companies across the country. He has a particular focus in Hatch-Waxman pharmaceutical patent litigation, and he advises both brand-side and generic-side companies at every stage, including pre-litigation strategy, notice letter preparation and evaluation, and settlement negotiation and enforcement.  Deming also regularly litigates Hatch-Waxman cases involving drug product types such as ophthalmic, solid oral, controlled release, transdermal, and topical dosage forms. He is a registered patent attorney and was admitted to practice before the United States Patent and Trademark Office in 2012.

“I am humbled by this promotion to chair Polsinelli’s industry-leading Hatch-Waxman Litigation Practice Group,” said Deming. “I am looking forward to further guiding our attorneys, scientists and patent agents as we continue to represent some of the world’s largest pharmaceutical companies, and to contributing to the firm’s future growth and success.”

Polsinelli’s Intellectual Property Department ranks nationally in Tier 1 for Patent Law, Trademark Law and Litigation – Intellectual Property in U.S. News and World Report’s 2022 “Best Law Firms.” As one of the largest IP practices in the nation, Polsinelli has a deep bench of attorneys, patent agents, scientists and other professionals who handle some of the most complex issues facing technology and high-tech companies, bioscience and life sciences companies, animal science, medical device, pharmaceutical, chemical, software and business methods.

About Polsinelli

Polsinelli is an Am Law 100 firm with more than 950 attorneys in 21 offices nationwide. Recognized by legal research firm BTI Consulting as one of the top firms for excellent client service and client relationships, the firm’s attorneys provide value through practical legal counsel infused with business insight, and focus on health care, financial services, real estate, intellectual property, middle-market corporate, labor and employment and business litigation. Polsinelli PC, Polsinelli LLP in California.